Scientists created DNA-based vaccine scaffolds. In mice, the approach generated more HIV-specific B cells than traditional ...

A novel HIV vaccine candidate induces neutralising antibodies after a single dose in primates, potentially accelerating HIV prevention.

Scientists at The Wistar Institute have developed an HIV vaccine candidate that achieves something never before observed in ...

South Africa has begun the first human trials of a locally developed HIV vaccine to defeat a virus that still kills around one person per minute worldwide.

So far, there is no "magic bullet" to cure HIV for good, but scientists are making rapid progress.

Broadly neutralizing antibodies, or bnAbs, are a long‑standing goal of HIV vaccine research because they can disable many strains of the virus at once.

The BRILLIANT 011 trial is testing two next-generation HIV vaccine components—BG505 GT1.1 and 426c.Mod.Core-C4b—administered ...

A twice-yearly injection described as the most promising HIV prevention tool in decades is poised to reach millions more people, with new generic versions priced at about $40 per patient per year. The ...

The BRILLIANT 011, a first-in-human clinical trial, was officially launched at the Desmond Tutu HIV Foundation (DTHF) ...

According to the Washington Post (WP) and others on the 4th, local time, Fiji—with a population of less than 1 million—has ...

International guidelines recommend anal and liver surveillance for people with HIV, but Brazil lacks a national protocol; clinicians should integrate screening and vaccination.